Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Research & Development (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Research & Development for 12 consecutive years, with $33524.0 as the latest value for Q3 2024.

  • On a quarterly basis, Research & Development fell 5.13% to $33524.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $153685.0, a 27.61% decrease, with the full-year FY2025 number at $11725.0, down 92.37% from a year prior.
  • Research & Development was $33524.0 for Q3 2024 at Regen BioPharma, up from $32500.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $95513.0 in Q4 2022 to a low of $12.0 in Q2 2020.
  • A 5-year average of $29820.6 and a median of $32500.0 in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 99.92% in 2020, then surged 118683.33% in 2021.
  • Regen BioPharma's Research & Development stood at $1127.0 in 2020, then surged by 3042.68% to $35418.0 in 2021, then surged by 169.67% to $95513.0 in 2022, then tumbled by 50.24% to $47528.0 in 2023, then decreased by 29.46% to $33524.0 in 2024.
  • Per Business Quant, the three most recent readings for RGBP's Research & Development are $33524.0 (Q3 2024), $32500.0 (Q2 2024), and $40133.0 (Q1 2024).